Physician profile
Jonnetta Hill
NPI 1063964237
$7,307.62
in general payments reported to CMS, 2019-2025
30 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,746 · 2022: $1,793 · 2023: $1,834 · 2024: $428 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $952.12 | 2021-2023 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $758.18 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.63 | 2021-2023 | Stiolto Respimat, Jardiance |
| Abbott Laboratories | $503.82 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $491.92 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $380.23 | 2021 | |
| Vanda Pharmaceuticals INC. | $342.02 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $285.36 | 2023-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $284.40 | 2021-2022 | |
| Glaxosmithkline, LLC. | $222.29 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $210.82 | 2021-2023 | Uzedy, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $184.95 | 2022 | |
| Lilly USA, LLC | $171.75 | 2021-2023 | Jardiance, Emgality |
| Sunovion Pharmaceuticals INC. | $136.81 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $133.48 | 2021-2023 | Loreev Xr, Sertraline Hcl, Venlafaxine |
| Corcept Therapeutics | $115.11 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $106.50 | 2025 | Voquezna |
| Dexcom, INC. | $67.41 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $56.90 | 2021-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Alkermes, INC. | $40.33 | 2023 | Vivitrol |
| Exact Sciences Corporation | $33.27 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.08 | 2022-2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $21.03 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $20.86 | 2021 | |
| Astellas Pharma US INC | $15.28 | 2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $14.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.04 | 2023 | |
| Amarin Pharma, INC. | $12.32 | 2021 | |
| Athena Bioscience, LLC | $10.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonnetta Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.